The FDA granted authorization for an Investigational Device Exemption (IDE) application involving Adaptive Biotechnologies.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted authorization for an Investigational Device Exemption (IDE) application involving Adaptive Biotechnologies.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Adaptive Biotechnologies
company in Seattle, United States
Nothing else this week.
Related events
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
- enVVeno Medical received IDE approval from the FDA for its pivotal study on July 31, 2026.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA approval expands patient access to therapies for ACCORD.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.